Multiple sclerosis – www.brainwork.md

9th July 2019

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Natalizumab.jpg 3067 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

Michael Furrer, PhD
0
0

9th July 2019

Serum NfL levels shine a light on neuroaxonal damage and disease

https://www.brainwork.md/content/uploads/2019/07/Brainwork-NfL.jpg 4089 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

The 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, featured an in-depth exploration of the role of neurofilament light chain (NfL) protein levels as a…

Michael Furrer, PhD
0
0

9th July 2019

Cellular power failures linked to Parkinsonism

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Parkinsonism.jpg 3150 2100 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 9th July 2019 9th July 2019

Mounting evidence is linking neurodegenerative disorders, such as Parkinsonism and dementia, with mitochondrial dysfunction.1 At the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, the…

Mea Holm, PhD
0
0

4th July 2019

8-year follow-up data of alemtuzumab presented

https://www.brainwork.md/content/uploads/2019/07/follow-up-data-of-alemtuzumab-presented-image.jpg 1920 1280 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 4th July 2019 9th July 2019

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

Michael Furrer, PhD
0
0

17th May 2019

Establishing sNfL as an MS Biomarker

https://www.brainwork.md/content/uploads/2019/05/Brainwork-MSBiomarkers.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

At the ECTRIMS annual congress in October 2018, there was a lot of talk on serum neurofilament light (sNfL) becoming the first blood biomarker predicting neuronal damage caused by neurological…

Carlotta Foletti, PhD
0
0

17th May 2019

News from the ocrelizumab front

https://www.brainwork.md/content/uploads/2019/05/Brainwork-NewsOcrelizumab.jpg 3300 2200 Carlotta Foletti, PhD Carlotta Foletti, PhD https://secure.gravatar.com/avatar/c8bf2814aa3641344dd6e3b11325ad20?s=96&d=mm&r=g 17th May 2019 17th May 2019

In our ongoing coverage of the AAN Annual Meeting in Philadelphia, we are focusing on select posters reporting on studies of ocrelizumab, an intravenous humanised monoclonal antibody that selectively targets…

Carlotta Foletti, PhD
0
0

31st January 2019

Stem-cell therapy puts the brakes on MS

https://www.brainwork.md/content/uploads/2019/01/Brainwork-StemCellStopMS.jpg 2850 1900 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 31st January 2019 1st February 2019

New data reveal the power of stem-cell transplantation in slowing or even halting disease progression in patients with RRMS, thereby reinvigorating further exploration of cellular treatments in MS. The findings…

Peter Stevenson, PhD
0
0

19th October 2018

Cognitive impairment in MS

https://www.brainwork.md/content/uploads/2018/10/Brainwork-MSCognitive_2048-1.jpg 2048 1153 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 19th October 2018 1st February 2019

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

Mea Holm, PhD
0
0

16th October 2018

Serum neurofilament light: A biomarker for disease activity in MS

https://www.brainwork.md/content/uploads/2018/10/MPR425-Brainwork-illustration-soluble-biomarkers-V00-03-20181012.jpg 1920 1080 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 16th October 2018 19th October 2018

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

Mea Holm, PhD
1
0

15th October 2018

Results from the MS-SMART trial unveiled

https://www.brainwork.md/content/uploads/2018/10/Brainwork-ECTRIMSSMART.jpg 3971 2975 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 15th October 2018 15th October 2018

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

Mea Holm, PhD
0
0